首页> 外文OA文献 >The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration
【2h】

The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration

机译:细胞表面含糖蛋白CUB结构域的蛋白1(CDCP1)有助于表皮生长因子受体介导的细胞迁移

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Epidermal growth factor (EGF) activation of the EGF receptor (EGFR) is an important mediator of cell migration, and aberrant signaling via this system promotes a number of malignancies including ovarian cancer. We have identified the cell surface glycoprotein CDCP1 as a key regulator of EGF/EGFR-induced cell migration. We show that signaling via EGF/EGFR induces migration of ovarian cancer Caov3 and OVCA420 cells with concomitant up-regulation of CDCP1 mRNA and protein. Consistent with a role in cell migration CDCP1 relocates from cell-cell junctions to punctate structures on filopodia after activation of EGFR. Significantly, disruption of CDCP1 either by silencing or the use of a function blocking antibody efficiently reduces EGF/EGFR-induced cell migration of Caov3 and OVCA420 cells. We also show that up-regulation of CDCP1 is inhibited by pharmacological agents blocking ERK but not Src signaling, indicating that the RAS/RAF/MEK/ERK pathway is required downstream of EGF/EGFR to induce increased expression of CDCP1. Our immunohistochemical analysis of benign, primary, and metastatic serous epithelial ovarian tumors demonstrates that CDCP1 is expressed during progression of this cancer. These data highlight a novel role for CDCP1 in EGF/ EGFR-induced cell migration and indicate that targeting of CDCP1 may be a rational approach to inhibit progression of cancers driven by EGFR signaling including those resistant to anti-EGFR drugs because of activating mutations in the RAS/ RAF/MEK/ERK pathway.
机译:EGF受体(EGFR)的表皮生长因子(EGF)激活是细胞迁移的重要介体,通过该系统的异常信号传导会促进包括卵巢癌在内的许多恶性肿瘤。我们已经确定细胞表面糖蛋白CDCP1是EGF / EGFR诱导的细胞迁移的关键调节剂。我们表明,通过EGF / EGFR的信号传导诱导卵巢癌Caov3和OVCA420细胞的迁移,并伴随CDCP1 mRNA和蛋白的上调。与细胞迁移中的作用一致,在激活EGFR后,CDCP1从细胞间连接重定位到丝状伪足上的点状结构。重要的是,通过沉默或使用功能阻断抗体来破坏CDCP1可以有效降低EGF / EGFR诱导的Caov3和OVCA420细胞的细胞迁移。我们还显示,阻断ERK而不是Src信号传导的药理作用可抑制CDCP1的上调,这表明RAS / RAF / MEK / ERK通路是EGF / EGFR下游诱导增加CDCP1表达所需的。我们对良性,原发性和转移性浆液性上皮性卵巢肿瘤的免疫组织化学分析表明,CDCP1在这种癌症的进展过程中表达。这些数据突显了CDCP1在EGF / EGFR诱导的细胞迁移中的新作用,并表明靶向CDCP1可能是抑制由EGFR信号驱动的癌症进展的合理方法,包括由于抗EGFR活化突变而导致的抗EGFR药物耐药的癌症。 RAS / RAF / MEK / ERK途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号